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Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies
directed against desmoglein-1 located in the upper epidermal layer. Rituximab, a
monoclonal anit-CD20 antibody depleting b-cells, offers an effective treatment possibility
for therapy-resistant pemphigus foliaceus. Here, we present the case of 55-year-old
man who did not respond sufficiently to conventional treatment with prednisolone,
azathioprine, and cyclophosphamide, but underwent almost complete remission after
rituximab treatment. The patient relapsed 7 years later, and a repeated course of
rituximab infusions led to a partial remission.
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INTRODUCTION
Pemphigus foliaceus is a rare, autoimmune blistering skin disease with an estimated incidence of
<1 million individuals in the USA and Europe (1). It is caused by autoantibodies directed against
desmoglein-1 (Dsg-1), a glycoprotein important for intercellular adhesion between keratinocytes
(2, 3). The disease manifests as erythematous papules, plaques, and erosions with scaly crusts. The
involvement of seborrheic skin areas is typical for the disease. The loss of adhesion occurs in the
upper epidermal layers and is limited to the skin with no mucosal involvement; this is attributable
to the expression pattern of Dsg-1 and distinguishes pemphigus foliaceus from the more common
pemphigus vulgaris (4, 5).
Glucocorticoids are the first-line treatment for pemphigus foliaceus. Treatment with other
immunosuppressants such as azathioprine, mycophenolate mofetil or methotrexate, is also
well-established (6). Recent data suggest that a b-cell-depleting therapy with rituximab is highly
effective in treating pemphigus vulgaris, but also pemphigus foliaceus (7–10). Here, we describe
the case of a patient suffering from a therapy-resistant pemphigus foliaceus; the patient was in
remission for 7 years after initial rituximab treatment and responded well to the repeated treatment.
CASE PRESENTATION
A 55-year-old man with a history of progressing skin lesions over the past 8 months visited
our department for the first time in spring 2011. The clinical examination revealed multiple
erythematous papules and plaques with crusts on his back, chest, face, and scalp (about 40% of body
surface area was involved) with nomucosal involvement (Figure 1). The patient presented no other
symptoms and had no chronic diseases or allergies. His blood tests revealed a highly elevated Dsg1
antibody level (130 U/ml; normal range < 20 U/ml) and a slightly elevated γ-glutamyltransferase
level. Differential blood count, liver enzymes, creatinine, and Dsg3 antibody level were within
the normal range. Histological examination of the patient’s skin biopsy revealed an inflammatory
infiltrate, eosinophilic spongiosis, and superficial epidermal blister formation.
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FIGURE 1 | Skin lesions before rituximab treatment.
Based on the findings, pemphigus foliaceus was diagnosed
and a treatment with prednisolone (10 mg/day) and azathioprine
(100 mg/day) was started. Topical therapy with clobetasol
propionate and chlorhexidine was also initiated. Furthermore,
methylprednisolone infusions (750mg) were administered
once a month for 3 months. This treatment did not result in
complete remission; thus, methylprednisolone was replaced
with dexamethasone (300mg) and cyclophosphamide
infusions (500mg) once a month. Azathioprine had to be
discontinued due to increasing liver enzymes. The treatment
with cyclophosphamide and glucocorticoids was discontinued
after 5 months without achieving remission. Hence, we next
treated the patient with rituximab. Therefore, two rituximab
infusions (1 g each) were administered 2 weeks apart leading to
a near-complete b-cell depletion in peripheral blood, a decrease
in Dsg1 antibody levels (below the detection range), and an
almost complete remission of the skin lesions within the next
year (Figure 2). Consecutively, therapy with prednisolone (10
mg/day) and topical mometasone furoate was continued and
in the following 2 years, the prednisolone dose was reduced
to 5 mg/day. The patient remained in remission for 7 years
with this therapy (with Dsg1 antibody levels continuously
within the normal range). However, in autumn 2017, skin
lesions reappeared, which was accompanied by an increase in
the Dsg1 antibody levels (75 U/ml). The prednisolone dosage
was increased (temporarily up to 60 mg/day), but it was not
sufficient to control the disease. Therefore, rituximab infusions
(2 × 1 g within 14 days) were readministered, which led to slow
continuous healing of the skin lesions.
DISCUSSION
Numerous case reports and studies have reported on the efficacy
of rituximab in treating pemphigus vulgaris but also pemphigus
FIGURE 2 | Clinical picture eight months after initial rituximab treatment.
foliaceus (1, 7–11). Recently, Joly et al. (10) published a
randomized, multi-center, open-labeled clinical study comparing
rituximab and prednisolone as the first line of treatment for
pemphigus. The study subjects were treated with 1,000mg
rituximab on days 0 and 14, followed by 500mg rituximab after
12 and 18 months and 0.5–1 mg/kg prednisolone tapered over
3–6 months. The control group was treated with 1–1.5 mg/kg
prednisolone tapered over 12–18 months. After 2 years, the
achieved remission rates were 89 and 34% for the rituximab and
the control group, respectively. In the control group, the rate
of serious adverse events was twice as high as that among the
rituximab-treated group.
Thus, rituximab is effective in treating pemphigus foliaceus;
however, its ideal dosage regimen is still unknown. In most cases,
either 375 mg/m² rituximab is administered once a week for 4
weeks (lymphoma protocol) or two doses of 1,000mg rituximab
are administered 2 weeks apart (rheumatoid arthritis protocol).
In their comprehensive review, Ahmed and Shetty (11) reported
that responder rates (in pemphigus vulgaris) for both protocols
were similar. Because of the low B-cell burden in autoimmune
diseases, some authors proposed a low dosage regimen (12–14).
Relapse of pemphigus after rituximab treatment is common
(15). In majority of the patients, remission can be maintained up
to a few years. A 7-year remission duration, as observed in the
current study, is not frequent. Joly et al. reported that 25% of
rituximab treated patients relapsed within 2 years (10). Colliou
et al. followed 21 rituximab treated patients for 7 years (16). The
relapse occurred in 81% of patients and was associated with either
persisting or, as in our case, reincreasing Dsg antibody levels. The
factors influencing the remission time are not well-characterized
(17). The associations between prolonged time to relapse and
either higher number of rituximab cycles or a high-dose regiment
were described (7, 15, 17, 18). On the other hand, prophylactic
administration of an additional rituximab infusion in patients in
remission was shown not to be beneficial (19). Saleh (20) reported
a correlation between Dsg1 antibody levels at baseline and time
to relapse: patients with high levels of Dsg1 antibodies relapsed
usually within one year after rituximab treatment, while patients
Frontiers in Medicine | www.frontiersin.org 2 November 2018 | Volume 5 | Article 315
Kraft and Worm Pemphigus Foliaceus—A Case Report
with low Dsg1 antibody levels stayed in remission for about 2
years. Interestingly there was no association between time to
relapse and Dsg3 antibody levels or clinical severity at the time
of rituximab treatment.
In a recent small study, Keeley et al. reported that a
low-dose maintenance immunomodulatory treatment
after rituximab therapy might prevent a relapse (21).
Ahmed et al. observed no relapses in ten patients treated
with immunoglobulins and rituximab (22). The adjuvant
immunoglobulins were administered in average for 34
months following the rituximab treatment and a long-lasting
remission was achieved in all patients [average follow up
was 7 years after the initial rituximab treatment (22)]. In
our patient, it is probable that the prolonged remission
was supported by the continuous low-dose prednisolone
therapy.
As here observed, treatment with rituximab is successful in the
majority of the patients after relapse (15, 18, 23) so that repeated
treatment can be recommended for these patients.
Serious adverse event following rituximab treatment are rare.
Those are mostly infections (e.g., viral hepatitis reactivation, or
herpes virus infections) (24). Few cases of infections with lethal
outcomes after rituximab treatment have been reported (24);
thus, patients and physicians should be aware of this risk and
immediately act in case of suspected adverse event.
CONCLUDING REMARKS
Our case report demonstrates that rituximab can be effective in
treating therapy-resistant pemphigus and long-lasting remission
may be achieved. A low-dose maintenance immunomodulatory
treatment after rituximab therapy may prolong the remission
stage. In case of a relapse, repeated treatment with rituximab is
usually successful. However, this therapy is limited due to the
high cost of rituximab and the risk of rare but severe side effects.
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